首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   34篇
  免费   11篇
医药卫生   45篇
  2023年   1篇
  2021年   3篇
  2020年   2篇
  2019年   2篇
  2018年   7篇
  2017年   10篇
  2015年   9篇
  2013年   4篇
  2012年   5篇
  2011年   1篇
  2008年   1篇
排序方式: 共有45条查询结果,搜索用时 78 毫秒
11.
焦久存  王彩娟  魏晓珊 《河北中医》2012,34(11):1645-1647
目的 观察温胆汤对湿热质脑梗死患者二级预防的临床疗效.方法 将110例湿热质脑梗死患者随机分为2组,对照组55例予阿司匹林肠溶片治疗,治疗组55例在对照组治疗基础上应用温胆汤治疗.2组均治疗6个月.观察2组疗效,比较治疗前后临床神经功能缺损评分、日常生活活动能力(ADL)量表(Barthel指数)、中医证候评分的变化.结果 治疗组治疗后临床神经功能缺损评分较本组治疗前、对照组治疗后均降低(P <0.05,P<0.01).治疗组治疗后Barthel指数较本组治疗前、对照组治疗后均升高(P<0.05,P<0.01).治疗组治疗后中医证候评分较本组治疗前、对照组治疗后均降低(P<0.05,P<0.01).治疗组总有效率89.09%,对照组总有效率76.36%,2组总有效率比较差异有统计学意义(P<0.05),治疗组疗效优于对照组.结论 温胆汤对湿热质脑梗死患者二级预防有一定的疗效,是临床预防脑梗死安全有效的方法之一.  相似文献   
12.
脑梗死恢复期痰证与血脂代谢关系的临床观察   总被引:1,自引:0,他引:1  
目的探讨脑梗死恢复期痰证与血脂代谢的关系。方法将脑梗死恢复期患者103例按辨证分型分为2组,痰证组52例,非痰证组51例;并设正常对照组50例,为老年体检者(健康人)。评定痰证组和非痰证组临床神经功能缺损积分,并检测3组总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)水平。结果脑梗死恢复期痰证组临床神经功能缺损积分(22.91±11.15)分,非痰证组临床神经功能缺损积分(12.10±8.19)分,2组比较差异有统计学意义(P<0.01);脑梗死恢复期TG、TC、LDL-C均较正常对照组显著升高(P<0.01);痰证组TG、TC、LDL-C较非痰证组明显升高,2组比较差异均有统计学意义(P<0.05,P<0.01)。结论脑梗死恢复期存在严重的血脂代谢紊乱,临床应注重化痰以促进神经功能恢复和身体康复。  相似文献   
13.
14.
15.
The JNK and p38α pathways play an important role in carcinogenesis. Therefore, we hypothesize that single nucleotide polymorphisms (SNPs) of genes involved in these pathways are associated with risk of lung cancer. We first selected and genotyped 11 independent SNPs of the JNK and p38α pathway‐related genes in a discovery set of 1,002 non‐small cell lung cancer (NSCLC) cases and 1,025 cancer‐free controls of Eastern Chinese. Then, we validated those significant SNPs in a replication set of 1,333 NSCLC cases and 1,339 cancer‐free controls of Eastern Chinese. Multifactor dimensionality reduction (MDR) and classification and regression tree (CART) analyses were used to identify interactions between significant SNPs and other covariates. In both discovery and replication as well as their pooled analysis, carriers of GADD45G rs8252T variant genotypes had a significantly lower risk of NSCLC (adjusted OR = 0.81 and 0.79, 95% CI = 0.72–0.92 and 0.64–0.99 and p = 0.001 and 0.040 for dominant and recessive genetic models, respectively) and carriers of MAP2K7 rs3679T variant genotypes had an increased risk of NSCLC (adjusted OR = 1.19 and 1.29, 95% CI = 1.05–1.34 and 1.09–1.54 and p = 0.005 and 0.004 for dominant and recessive genetic models, respectively). Furthermore, rs8252 variant CT/TT carriers showed significantly higher levels of GADD45G mRNA expression than CC carriers in the target tissues. We observed some evidence of interactions between rs8252 genotypes and sex in NSCLC risk. These results indicate that GADD45G rs8252 and MAP2K7 rs3679 SNPs may be susceptibility biomarkers for NSCLC in Eastern Chinese populations.  相似文献   
16.
17.
18.
[目的]观察补阳还五汤加减对气虚质脑梗塞恢复期二级预防的疗效及其安全性。[方法]将107例气虚质脑梗塞恢复期患者按先后顺序随机分为观察组54例和对照组53例。两组在常规治疗的基础上,观察组予补阳还五汤加减辩证治疗6个月,同时给予口服阿司匹林;对照组给予口服阿司匹林;两组均随访6个月。比较两组患者缺血性脑卒中复发率、临床神经功能缺损、日常生活活动能力和中医症状评分的改善情况以及中药辩证施治的安全性。[结果]两组复发率差异无统计学意义(P〉0.05);在改善临床神经功能缺损评分、日常生活活动能力评分、中医症状评分方面,观察组优于对照组(P〈0.01);均未出现严重不良反应。[结论]补阳还五汤加减对气虚质脑梗塞恢复期二级预防有一定的疗效,是临床预防脑梗塞安全有效的方法之一。  相似文献   
19.
In this work, we successfully fabricate a rapid, sensitive sensor for the detection of superoxide anions O2˙ based on graphene/DNA/Mn3(PO4)2 biomimetic enzyme. In the design, graphene is served as excellent carrier to improve the catalysis of Mn3(PO4)2 nanoparticles; and DNA adsorbed on graphene acts as medium to assist the growth of Mn3(PO4)2 on graphene. The fabricated graphene/DNA/Mn3(PO4)2 composites exhibit excellently electrochemical activity, significantly decrease the response time and increase the sensitivity of the sensor towards O2˙. The successful detection of O2˙ released from cancer cell demonstrated its potential applications in biology and medicine.

In this work, we successfully fabricate a rapid, sensitive sensor for the detection of superoxide anions O2˙ based on graphene/DNA/Mn3(PO4)2 biomimetic enzyme.  相似文献   
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号